Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees

Apr 08 2018

• By Sue Sutter and Derrick Gingery

Woman counting dollars at table

Related Content

Hamburg, Like Industry, Wants Predictability – But In FDA Funding

Nov 06 2013

FDA May Not Implement User Fee Workload Adjuster In PDUFA VI

Apr 02 2018

21st Century Cures Now A Partially Funded Mandate For FDA

May 21 2015

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

FDA's GDUFA War Chest Grows, And Industry May Look For Lower Fees

Jun 08 2015

Biosimilar User Fee Collections Rise, But Little Spent On Program Costs

Apr 25 2016

PDUFA VI Might Adjust Establishment Fees; FDA Aims For Simplification

Nov 16 2015

Additional Topics

United States Drug Review Generic Drugs Biosimilars FDA Policy BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.